Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.79) by 12.66 percent. This is a 258.93 percent decrease over earnings of $0.56 per share from the same period last year.